|
Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Ipsen; Oncorena; Pfizer |
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Ipsen; Oncorena; Pfizer |
Research Funding - BMS France (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BMS; Ipsen; MSD |
|
|
No Relationships to Disclose |